Lipid-drug conjugates: a potential nanocarrier system for oral drug delivery applications
- 417 Downloads
Hydrophilic drugs are preferred candidates for most routes of drug administration, because of their enhanced solubility and dissolution under aqueous in vivo conditions. However, their hydrophilic nature also leads to decreased permeability across hydrophobic barriers. This is a severe limitation in situations where membrane permeability is the primary factor affecting bioavailability and efficacy of the drug. Highly impermeable cellular membranes or the tight endothelial junctions governing the blood-brain barrier are prime examples of this limitation. In other cases, decreased permeability across mucosal or epithelial membranes may require increased doses, which is an inefficient and potentially dangerous workaround. Covalent conjugation of hydrophilic drugs to hydrophobic moieties like short-chain lipids is a promising strategy for maintaining the critical balance between drug solubility and permeability. This article practically focuses on the production procedure of Lipid drug conjugates (LDCs), various formulation methodologies for preparing LDC nanoparticles with detailed about their in vitro physicochemical characterization at laboratory scale. Moreover, brief overviews on the role of LDCs in novel drug delivery applications as a substrate to various disease therapies are provided.
KeywordsLipid drug conjugates Oral administration Drug delivery Hydrophilic drug
Lipid Nanoparticle Formulations
Biopharmaceutical Classification Systems
The authors are thankful to their respective institution and university for providing access to necessary literature resources and essential library facilities for writing this review article. Recognition also goes to all the authors of papers, books, patents, websites and all other published sources listed in the references that were used to prepare the contents of this review article.
Compliance with ethical standards
Consent for publication
Declaration of interest
The authors declare that they have no competing interests.
- 1.Anthony AA, Mumuni AM, Philip FB. Lipid Nanoparticulate Drug Delivery Systems: A Revolution in Dosage Form Design and Development. Recent Advances in Novel Drug Carrier Systems. Intech Open; 2012. Pp. 107–140.Google Scholar
- 5.Das RJ, Baishya K, Pathak K. Recent advancement of lipid drug conjugate as nanoparticulate drug delivery system. Int Res J Pharm. 2013;4(1):73–8.Google Scholar
- 15.Wen B, Sun Y, Xu Y, Sun J, Liu X, Wang Y, et al. Pharmacokinetic characteristics of the cytarabine prodrug, ilecytarabine, after intravenous and oral administration to rats. Asian J Pharm Sci. 2008;3:200.Google Scholar
- 19.Charman WN, Stella VJ, editors. Lymphatic transport of drugs. Boca Raton: CRC Press; 1992.Google Scholar
- 36.Schwarz C, Freitas C, Mehnert CW, Muller RH. Sterilization and physical stability of drug-free and etomidate- loaded solid lipid nanoparticles. Proc Int Symp Control Release Bioact Mater. 1995;22:766–7.Google Scholar
- 39.Sari A, Akcay M, Soylak M, Onal A. Polymer-stearic acid blends as form-stable phase change material for thermal energy storage. J Sci Ind Res. 2005;64:991–6.Google Scholar
- 46.Stela G, Esther I. Conjugates for cancer therapy and diagnosis, patent application number: 20110275590; Publication date: 11, October (2011).Google Scholar
- 47.Wyatt DA. Taking poorly water-soluble compounds through discovery. In: Recent advances in the formulations and development of poorly soluble drugs. Bulletin Technique Gattefosse. 1999:31–39.Google Scholar